cpsa europe 2019 meeting programme · robert buco waters mateus campos sciex kyle d’silva thermo...

MEETING PROGRAMME

Milestone Development Services

2ND ANNUAL SYMPOSIUM

Clinical & Pharmaceutical Solutions through Analysis

Where Technology and Solutions Meet

Technology for the Patient

February 5– 8, 2019Cambridge Belfry HotelCambourne, Cambridge U.K.

Introducing the first SmartMS-enabled biopharma solutionAn integrated LC-MS system with intelligent software, chemistries, and service

& support that ensures:

Reproducible data with simple set-up for any user

Streamlined workflows from sample to result

Rapid identification and resolution of issues with no need for specialist expertise

Compliance-ready features that reduce risk and simplify audit preparation

Success in intact mass analysis, peptide mapping, and released glycan applications

www.waters.com/BioAccord


February 5, 2019

Dear Colleagues:

On behalf of the organizing committee and our sponsors, it is our pleasure to welcome you to the 2nd Annual European Symposium on Clinical and Pharmaceutical Solutions through Analysis (CPSA Europe 2019). The meeting, along with related events, promises to be both exciting and timely as well as feature lively discussions, memorable interactions, and the sharing of real-world experiences.

The goal of CPSA Europe is to provide in-depth review of innovative technology and industry practices through open discussion of industry-related issues and needs. This annual event is specifically geared to the needs of professionals attempting to keep pace with faster development times and technology marketing managers attempting to benchmark emerging trends.

We are extremely delighted to feature a most distinguished plenary speaker, Hitesh Pandya of GlaxoSmithKline. His lecture on “What Solutions are Needed to Meet the Health Needs of Future Generations?” reflects an all too common theme in planning for the future of healthcare and rapidly advancing technology. The combination of such diverse interests, issues, and needs will provide unique perspectives, and certainly, continue to inspire significant advances.

The symposium sessions provide a wonderful opportunity to interact with industry leaders as well as openly share experiences – from the laboratory to the patient. Specific issues and needs from previous CPSA annual meetings in the USA, China and Brazil will help drive the agenda at CPSA Europe with a focus on sharing and collaboration to develop next generation tools and services to further human healthcare.

Our hope is that you will actively participate, interact, and share ideas during the event. Creativity and imagination have been key ingredients to make CPSA meetings a memorable experience all over the world. In this way, a genuine passion for the analytical sciences can lead to personal growth as well as opportunities to significantly impact the field through participation, leadership, and global citizenship.

The hallmark of CPSA Europe is identical to other CPSA events – belief in a notion that simple actions, simple gestures, along with relationships can bring people together to cooperate in a most transparent and inclusive manner – which when sustained in a coordinated fashion can result in spectacular dreams that are destined to come true. And so, at CPSA Europe, we dare to attempt to do something great. Together.

Special thanks go to the sponsors of CPSA Europe. In particular, we wish to thank Waters, Merck, New Objective, Spooner Bioanalytical Solutions, and Molecular Discovery together with Alturas Analytics, Bioanalysis, Capitainer, Celta Ingenieros, Elucidata, IMCS, Perkin Elmer, PRA Health Sciences, Prolab, Neoteryx, Scientific Instrument Services, SCIEX, Shimadzu and Trajan for giving this meeting life. Thank you! All CPSA sponsors share the passion and commitment for both innovative technologies and the advancement of personalized healthcare.

Enjoy the second annual meeting – where technology and solutions meet!

Sincerely,

WELCOME

Mike S. Lee, Ph.D.CPSA Founder

Neil Spooner, Ph.D.CPSA Europe Programme Co-Chair

Ismael Zamora, Ph.D.CPSA Europe Programme Co-Chair


2Where Technology and Solutions Meet

ORGANISING COMMITTEE

PROGRAMME CO-CHAIRS

Neil SpoonerSpooner Bioanalytical Solutions

Marie Alqvist AstraZeneca

Linda Barr New Objective

Matt Barfield GlaxoSmithKline

Rafael BarrientosEurofarma

Kevin BatemanMerck

Natália Bellan Sanitary Intelligence

Amanda Berg New Objective

Britta Bonn AstraZeneca

David BrownPRA Health Sciences

Robert Buco Waters

Mateus Campos SCIEX

Kyle D’Silva Thermo Fisher Scientific

Tony Edge Agilent Technologies

Emily EhrenfeldNew Objective

Ute GerhardUniversity of Hertfordshire

Arkady GusevNovartis

Gérard HopfgartnerUniversity of Geneva

Emre IsinUCB

Carlos KifferGC-2

Daniel LebreCEMSA Laboratories

Neil LoftusShimadzu

Thiago Mares GuiaBionovis

Sarah MayesFuture Science Group

Stephen McDonaldWaters

Darragh MurnaneUniversity of Hertfordshire

Shane NeedhamAlturas Analytics

Axel PählerRoche

Hitesh PandyaGlaxoSmithKline

James RudgeNeoteryx

Pawanbir SinghTrajan Scientific & Medical

Joe SipleNew Objective

John SmeralgiaUCB Pharma SA

Christophe StoveGhent University

Liz ThomasAlderley Analytical

Jaap WielingAntaeus Biopharma BV

Amanda WilsonAstraZeneca

Jason WrigleyMerck (Millipore/Sigma)

Eric YangGlaxoSmithKline

LOGISTICS & MANAGEMENT

Logistics & Communications

Carla Marshall-WaggettNew Objective

Management & Correspondence

Mike LeeMilestone Development Services

SYMPOSIA & SESSIONS

Ismael ZamoraMolecular Discovery

3 Technology for the Patient

SPONSORSThank You

The CPSA Europe Symposium is made possible by the broad-based support of industry sponsors. The passion for the analytical sciences and the accelerated discovery and development of technology and services is shared by each sponsor. As a result, the event is dedicated to promoting awareness and understanding of the issues and needs associated with research and development in the hopes of inspiring significant advances in the field.


WORKSHOPSTuesday February 5

TUES

DA

Y, F

EBRU

ARY

5

12:00 PM REGISTRATION

Main Lobby

1:00 PM - 4:30 PM WORKSHOP

Sponsored by Merck (MilliporeSigma in USA/Canada)

Magdalene Room If Our Own Scientific Community Does Not Have the Answer Where Do We Look?

Workshop Leader: Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

This workshop starts with the premise that as specialists in a particular field we are not always necessarily the best people to develop and implement novel technological approaches. As such, it will provide an overview of where we currently are with this and what we do. This will be followed by an open floor discussion to see where we could go and look for ideas and solutions. This session does not have the answers but is looking to the audience to think differently and brainstorm where we might go and look for some answers/solutions. A fun and serious discussions will be concluded with action points for follow up to see if we really can find some novel (to our industry!) solutions. Think big!!


Sponsored by New Objective

Queen’s Room The Future of Personalized Healthcare: Integrated Solutions

Workshop Leader: Emily Ehrenfeld, New Objective

This solutions based workshop will explore how we generate and utilize quantitative data for human healthcare and wellbeing. Established workflows for the generation of quantitative analytical data used for decision making by clinicians, pharmaceutical companies, central clinical laboratories and academics have remained essentially unchanged for decades. This approach has suited the established means of one size fits all approach to delivering healthcare. However, this approach is no longer ideal, or indeed sustainable. Personalized medicines and treatments are increasingly becoming the norm. Further, technologies are enabling patient sampling and subsequent analysis to be performed in locations and with technologies that are more patient centric and importantly, many subjects are taking a more active interest in their own medical data and the decisions resulting from it. This paradigm shift calls for a change from the established workflows. This Workshop will explore these changes, their implications and what a new normal might look like in 5-10 years time. We welcome you to join our discussion.

Panel Discussion: Matt Barfield, GlaxoSmithKline; Kevin Bateman, Merck; Ute Gerhard, University of Hertfordshire; Bernhard Nemec, Prolab Instruments; Hitesh Pandya, GlaxoSmithKline; Pawanbir Singh, Trajan Scientific and Medical; Neil Spooner, Spooner Bioanalytical Solutions

6:00 PM - 9:00 PM OPENING RECEPTION

College Suite Say hello to old friends and introduce your self to new!

Refreshments and light buffet served.



Wednesday February 6

PROGRAMME

WED

NESD

AY, FEBRU

ARY

6

7:00 AM - 8:30 AM BREAKFAST & REGISTRATION

Breakfast - Bridge Restaurant Registration - Main Lobby (7:30 AM)

8:30 AM OPENING REMARKS

The University Suite Welcome Mike Lee, Milestone Development Services

Format, Objectives, Opening Remarks

Neil Spooner, Spooner Bioanalytical Solutions Ismael Zamora, Molecular Discovery

8:45 AM - 9:45 AM PLENARY LECTURE

The University Suite What Solutions are Needed to Meet the Health Needs of Future Generations?

Hitesh Pandya, GlaxoSmithKline

The terms health and healthcare apply encompass people, populations, systems, processes and structures.

Innovation, change and investment have been the hallmarks of health and healthcare delivery over the past 200 years. Compared to 1800’s, people now live much longer. They are also less likely to die in early life as a result of complications at birth or lethal disorders such as cystic fibrosis and can live with a relative good quality of life with chronic conditions such as diabetes and asthma.

While spending on health and healthcare will continue at current levels for the foreseeable future, it seems unlikely that present levels of spending can afford the innovations and change required to meet the health needs of people with multiple chronic diseases living longer. One emerging unmet need in healthcare is complexity. Complexity in health refers to managing people with multiple disorders and analysing the vast and disparate amounts of data about them (demography, lifestyle, genetics, laboratory tests etc.) and their ailment(s) to determine optimal treatments.

Can we reduce the number of women needing costly IVF therapy to have babies? Am I over-eating and what foods will stop me getting fat? How can I sleep better for better mental health? How well we deal with the challenges of healthcare has always impacted on society. This presentation outlines a future where people are empowered to manage their health firstly to keep them from becoming ill and if unwell, how best to manage their ailments in the community. What solutions do we need to make this happen?


Wednesday FEBRUARY 6

PROGRAMME

9:45 AM - 11:15 AM SYMPOSIUM SESSION SESSION 1

The University Suite Pushing the Boundaries of Sample Collection – Near and Small

Discussion Leaders: Matt Barfield, GlaxoSmithKline; Emily Ehrenfeld, New Objective

� GSK Centre for FTIH Research—A Patients, Clinicians and Analysts PerspectiveJames Ritter, Pauline Kitchiner, and Bill Davis GSK Clinical Unit, Addenbrooke’s Hospital

� Patient Centric Sampling and Analysis: How Might We Progress the Agenda and What Might the Outcome Look Like?Neil Spooner, Spooner Bioanalytical Solutions

� Why Aren’t We Doing Patient Centric Sampling?Kevin Bateman, MSD (Merck & Co. in USA/Canada)

11:15 AM - 12:45 PM SYMPOSIUM SESSION SESSION 2

The University Suite Emerging Technologies to Enable a Paradigm Shift from “Sick Care” to “Health Care”

Discussion Leaders: Emre Isin, UCB; Pawanbir Singh, Trajan Scientific and Medical

The primary goal for pharmaceutical industry is to develop medicines with the right exposure, reach the right target and treat the right patient. However, in the present information rich world, the ultimate objective is not only to control symptoms and treat disease but provision of technologies that facilitate both disease prevention and disease management. The enormity of this objective requires a transformative change. On one hand, there is the need to develop and have access to novel technologies which accelerate the drug development process and on the other, novel tools that enable a prevention model by focusing on forestalling disease development before clinical manifestation.

The objective of this session is to discuss emerging technologies and avenues to facilitate a paradigm shift from “sick care” to “health care”

� Utilising a Therapeutic Drug Monitoring Approach for the Treatment of Childhood Cancer Patients in the UK – Development of a National Programme of WorkGareth Veal, University of Newcastle

� From Bench to Bedside: The Growing Use of MS-Based Molecular Profiling in Intraoperative DiagnosticsTiffany Siegel, The Maastricht Multimodal Molecular Imaging Institute (M4I), Maastricht University

12:45 PM - 2:15 PM SPONSORED LUNCH & ROUNDTABLE

The College Suite The Future of Personalised Healthcare: Integrated Solutions – Mapping a Path Forward for Microsampling and Separations


Discussion Leaders: Matt Barfield, GlaxoSmithKline; Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

WED

NES

DA

Y, F

EBRU

ARY

6

PROGRAMME


Wednesday FEBRUARY 6

WED

NESD

AY, FEBRU

ARY

6


The University Suite Developing Novel Analytical Technologies: Understanding the Requirements of the Patient

Workshop Leaders: Britta Bonn, AstraZeneca; Ute Gerhard, University of Hertfordshire; Emre Isin, UCB; Darragh Murnane, University of Hertfordshire

Have you ever stopped to think about how many new technologies you have seen presented at conferences as clinical diagnostic and monitoring tools that have failed to take root? What about those blank faces staring at you as you discuss sampling errors, matrix interference effects and wonder why the clinical laboratory doesn’t want to buy your instrument? In this workshop session you will have the opportunity to hear from and talk with a patient about what drives their decision-making in their healthcare management. You will also have the opportunity to hear about what a clinician really needs to be able to make clinical decisions that matter to them. Further, you will have the opportunity to discuss with clinicians and patients about how well-designed analytical tools can transform lives, not just clinical care.

4:00 PM - 5:30 PM SYMPOSIUM SESSION SESSION 3

The University Suite Data in the 21st Century: Who owns it? Who can access it? Who pays for it? Who believes it?

Discussion Leaders: Laura Dormer, Future Science / Bioanalysis; Shane Needham, Alturas Analytics

� The Publisher PerspectiveLaura Dormer, Future Science Group

� The Pharma PerspectiveChris Rains, Shire Pharmaceuticals

5:30 PM CPSA EUROPE GROUP PHOTO

The University Suite Please gather together to capture the 2nd Annual CPSA Europe meeting with a group photo–including organizers, speakers, attendees–everyone!

6:00 PM - 8:00 PM SPONSORED DINNER & RECEPTION

The College Suite Sponsored by Waters Corporation

PROGRAMME


Thursday FEBRUARY 7

THU

RSD

AY,

FEB

RUA

RY 7


Breakfast - Bridge Restaurant Registration - Lobby (7:30 AM)


The University Suite Mike Lee, Milestone Development Services Neil Spooner, Spooner Bioanalytical Solutions

Ismael Zamora, Molecular Discovery


The University Suite Moving the Needle – Intact Biomolecule Quantification

Discussion Leader: David Browne, PRA Health Sciences; Rob Buco, Waters Corporation


The University Suite Using Technology to Improve Medical Adherence?

Discussion Leaders: Kevin Bateman, Merck; James Rudge, Neoteryx

� Identifying Medication Nonadherence Could Save £BillionsGraham Lawson, De Montfort University

� Forming a patient-doctor alliance through home TDMJ.J. Kim, Nottingham Children’s Hospital

� The Fallacy of Adherence in Clinical Trials, and the Value of Technology as an Impartial ObserverMatt Moyer, MSD (Merck & Co. in USA/Canada)

� On-Demand High-Content Drug Adherence and Biomarker MonitoringErwin Berthier, Tasso Inc.


The University Suite Extraordinary Measures - Are We Measuring the Right Thing?

Discussion Leaders: Ute Gerhard, University of Hertfordshire; Darragh Murnane, University of Hertfordshire; Christophe Stove, University of Ghent

The objective of the session will explore the challenges involved in measuring the right molecule, from the right matrix at the appropriate time points to really understand DMPK-PD phenomena.

� “Hiding in Plain Sight” Nanoparticle Bioanalysis - Can’t See the Wood for the TreeAaron Smith, AstraZeneca

� “Gone Girl” A Disconnect Between What’s Easy to Measure and EfficacyDeanne Rudd, Merck

Microsampling

Intervention

Diagnose

Test

www.trajanscimed.comScience that benefits people

Is accuracy and precision important to your blood work?

Does hematocrit impact the quantitation of your analysis?

Are you looking at patient centric sampling?

Trajan Scientific and Medical

It’s about enabling samples to be taken that would or could not otherwise be taken, to drive information rich decision making.

At Trajan, our mission is to provide easy-to-use tools that enable the remote and minimally invasive collection of biological samples, that are affordable and preserve sample integrity, whilst being simply integrated in to current laboratory workflows.

Talk with us around your sampling needs, as we are able to deliver full support from product design, system integration, manufacturing, logistics and go-to market strategies.

• Personal choice• Clinician driven change

• Interpretation of the results and what they mean

• Big data based on GOOD data

• Qualified laboratory services• Workflow integration

• Sample integrity • Ease of use• Accessible and affordable

ED

-075

1-G

© T

raja

n S

cien

tific

Aus

tral

ia P

ty L

td 0

1/20

19

www.moldiscovery.com

MetaSite/MassMetaSite/MassChemSite/Webmetabase

Vendor neutral. Multiple Acquisition Modes (DDA, IDA,

Mse, IMS, SWATH, AIF, Al, BBA)

Data

I \ Knowledge Information

...... Defining the field in Mass Spectrometry • Structure elucidation for bio and chemical

research in small and peptide molecules• Lipidomics analysis

Order consumables and accessories on-line at http://store.shimadzu.comShimadzu Scientific Instruments Inc., 7102 Riverwood Dr., Columbia, MD 21046, USAFor Research Use Only. Not for use in diagnostic procedures.

CHANGES EVERYTHING

The newest model in the Ultra-Fast Mass Spectrometry

(UFMS) series, the LCMS-8060 offers an incomparable

fusion of LC-MS/MS speed and sensitivity to achieve new

levels of data quality.

Ultrafast TechnologiesThe LCMS-8060 incorporates Shimadzu’s proprietary

ultrafast technologies (UF Technologies) to enable:

■ polarity switching time of 5 msec

■ data acquisition scan speed of 30,000 u/sec

■ ultra-fast MRM measurements up to 555 ch/sec

Highest Sensitivity

A redesigned UF-Qarray ion optical system increases

ion transmission and signal intensity while reducing

background noise for the utmost in quantitative detection.

Outstanding DurabilityA robust design and easy maintenance allow highly reliable data even for high-throughput analysis of samples in challenging matrices.

Time for a change? Discover the LCMS-8060, the ideal solution for better data quality and higher throughput for a wide array of challenging and routine applications.

Learn more about Shimadzu’s Triple Quad LCMS-8060.Call (800) 477-1227 or visit us online atwww.ssi.shimadzu.com/8060

Shimadzu’s New Triple Quad LCMS-8060 Expands the Limits of LC-MS/MS Quantitation for Applications Requiring the Highest Sensitivity

LCMS-8060_ad_CPSA progrm.indd 1 9/6/16 10:22 AM

www.moldiscovery.com

MetaSite/MassMetaSite/MassChemSite/Webmetabase

Vendor neutral. Multiple Acquisition Modes (DDA, IDA,

Mse, IMS, SWATH, AIF, Al, BBA)

Data

I \ Knowledge Information

...... Defining the field in Mass Spectrometry • Structure elucidation for bio and chemical

research in small and peptide molecules• Lipidomics analysis

Where Technology and Solutions Meet!

Patient Focused


Patient Focused

Standardization for the Patient

Patient Focused

Solutions for the Patient

Where Together We Progress Where East Meets West

Mark your calendar!

© 2019 Milestone Development Services All rights reserved

October 28-31, 2019Philadelphia, PA USA

Program Chairs

Timothy OlahBritol-Myers Squibb

Neil SpoonerSpooner Bioanalytical

Solutions

February 5-8, 2019London, U.K.

Program Chairs

Neil SpoonerSpooner Bioanlytical

Solutions

Ismael ZamoraMolecular Discovery

March 11-13, 2019Atlanta, GA USA

Program Chairs

Abhishek JhaElucidata

Andrew LeeIMCS

April 10-12, 2019Shanghai, China

Program Chair

Min LiuMerck

May 6-9, 2019Boston, MA USA

Program Chairs

Alla KlossSanofi

Amanda BergNew Objective

August 19-21, 2019 Sao Paulo, Brazil

Program Chair

Carlos KifferGC2

www.cpsa-brasil.com www.cpsa-usa.comwww.cpsa-europe.com www.cpsa-shanghai.com www.cpsa-analytics.comwww.cpsa-metabolomics.com

Where Technology and Solutions Meet

PROGRAMME


Thursday FEBRUARY 7

THU

RSDA

Y, FEBRUA

RY 7

1:00 PM - 2:30 PM SPONSORED LUNCH & ROUNDTABLE

The College Suite Patient Centric Diagnostics – From Bedside Back to Bench

Sponsored by Merck (MilliporeSigma in USA/Canada)

How can we flip the common term “from bench to bedside” to be a more patient centric “Bedside Back to Bench?” Industry leaders will then present an overview of the current landscape. We will then open the discussion to try and find pragmatic solutions by collaboration.

� IntroductionJason Wrigley, Merck

� Story So Far for Cancer DiagnosticsSteven Pennington, Atturos

� Innovative “Real Time” Decisions - Bench at the BedsideJenny Royle, digitalECMT


The University Suite Evolving Ideas into Deployable New Technologies—Breaking Down Barriers

Workshop Leaders: James Rudge, Neoteryx; Amanda Wilson, AstraZeneca

Big data, AI, 3-D printing and a connected world are making it possible to have the spark of an idea in one field of science and have a ready-made prototype produced thousands of miles away - even within hours of the products conception! Furthermore, modern technology is such that the idea can propagate into other fields which are then potentially useful for many other applications including the original intended use. But how do we move to deploying these inventions into adopted novel workflows? What barriers need to be overcome to make this so? In this session, we are exploring 3 different areas where our modern world impacts the evolution of deployable technologies and how these technologies in-turn have the potential to evolve future bioanalytical and healthcare solutions.

4:00 PM - 5:30 PM SYMPOSIUM SESSION SESSION 7

The University Suite Biomarkers – An Emerging Role in Patient Centric Drug Development

Discussion Leaders: Britta Bonn, AstraZeneca; Axel Pähler, Roche

� From Animals to Patients and Back: Case Studies For Translational BiomarkersAxel Pähler, Roche

� PExA - A Non-Invasive Technique to Sample Biomarkers from the LungJörgen Östling, PExA

� Panel Discussion: Translational Biomarkers Status and TrendsBritta Bonn, AstraZeneca; Jörgen Östling, PExA; Axel Pähler, Roche; Neil Spooner, Spooner Bioanalytical Solutions

6:00 PM - 8:00 PM SPONSORED DINNER & RECEPTION

The College Suite The Future of Personalised Healthcare: Integrated Solutions – Mapping a Path Forward for Sample Preparation and Data


Discussion Leaders: Matt Barfield, GlaxoSmithKline; Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

PROGRAMME


Friday FEBRUARY 8

FRID

AY,

FEB

RUA

RY 8


Breakfast - Bridge Restaurant Registration - Lobby (7:30 AM)


The Peterhouse Room Mike Lee, Milestone Development Services Neil Spooner, Spooner Bioanalytical Solutions



The Peterhouse Room Big Data Science Guiding Patient Care

Discussion Leaders: Amanda Wilson, AstraZeneca; Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

The widespread application of omics and big data science is facilitating the transition from conventional to personalised medicine. Industry has become data intensive and there are unprecedented opportunities to utilise omics data integration to address biological questions that can improve patient outcomes.

Short presentations from Academia and Pharma to showcase the big data science technology and application in making drug development and patient care decisions will be given. This session will then allow science leaders to engage in an open format panel discussion to explore this area more fully.

� If Big Data is the Answer, What Was the Question?Ian Wilson, Imperial College

• (Metabon)Omic data from biobanking, epidemiology etc.—What can we extract?

• What might “Fit for purpose data” collection look like?

� Mass Spectrometry Tissue Imaging: Linking Drug Efficacy & Safety with Deep Cellular PhenotypingRichard Goodwin, AstraZeneca

� Patients Front and Centre: Enabling Personalized Healthcare with Data from Individuals and PopulationsIan Wilson, Imperial College

• Are you taking the tablets? - Are you sure? Taking guesswork out of the clinic with, targeted and specific multi-analyte drug (100’s) analysis

• And what else are you taking that you haven’t told me about? Semi-targeted analysis for OTC, herbal or obtained via the internet drugs that could interfere with data interpretation on patient outcomes made using the same multi-targeted assays

• Do we need these data?

PROGRAMME


Friday FEBRUARY 8

FRIDA

Y, FEBRUA

RY 8


The Peterhouse Room Mass Spectrometry Imaging: Emerging Advancements and Applications

Discussion Leaders: Ismael Zamora, Molecular Discovery; Sara Tortorella, Molecular Horizon

� Mass Spectrometry Imaging in the Pharmaceutical Industry – Continuum from Enzyme to PatientPeter Marshall, GlaxoSmithKline

� What’s Going on in Computer Vision Today and Why You Might CareVadim Fedorov, Lead Molecular Design

� Digging Into the Unknown Unknowns: Data Analytics Challenges of Mass Spectrometry ImagingSara Tortorella, Molecular Horizon


The Peterhouse Room Current Models for Performing Quantitative Bioanalysis in Pharma and CROs – Are They Working?

Discussion Leaders: Liz Thomas, Alderley Analytical; Neil Spooner, Spooner Bioanalytical Solutions

Pharmaceutical companies are currently wedded to outsourcing the majority of their quantitative bioanalytical work. This helps them to minimise their internal costs (capital, labour, infrastructure) and deal with the peaks and troughs in workload. For Contract Research Organisations, this would appear to be a time of feast. However, as there is so much competition in the sector and Pharma are driving costs down, the equation is not so simple. Add to this the fact that CROs need to make a profit. Does this mean that the quality vs cost equation is currently out of kilter for this process?

The session will explore the above premise through 10 min presentations from experts in the field and then look at what the solutions might be with a panel discussion.

� A View from PharmaScott Summerfield, GlaxoSmithKline

� A View from CROsJane Allanson, York Bioanalytical Solutions (Unilabs)

� Bioanalysis 4.0: Is Automation Part of the Solution?Nathan Hawkins, Anatune

� Pharma and CRO: Could a Technology Vendor Assist in Global HarmonisationJason Wrigley, Merck (MilliporeSigma in USA/Canada)

1:00 PM CLOSING REMARKS

The Peterhouse Room Mike Lee, Milestone Development Services Neil Spooner, Spooner Bioanalytical Solutions



2019 CPSA EVENTS

Feel good about your Pharma QC management?

Feel Better with MerckIf you seek absolute assurance about the rightness of your method development work, if you need to ensure regulatory compliance in quality control, if you require expertise as well as state-of-the-art tools and services during the drug discovery process, just visit www.sial.com/feel-better and feel better.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

MERC180007_ANZ_Feel_Better_Overall_Merck_210x297.indd 1 12.01.18 15:26

10th ANNUAL SYMPOSIUM


Translating Challenges in the Biotechnology Industry: From Drug Discovery to the Clinic

Solutions for the Patient: Building Communities One Patient at a Time

www.cpsa-shanghai.com

April 10–12, 2019 • Shanghai, China

Where Technology and Solutions Meet. Where East Meets West.

Program Chair Min Liu Merck

Program Chair Carlos Kiffer GC2

Plenary Speaker Mingqiang Zhang Amgen

Plenary Speaker Thiago Mares Guia Bionovis



www.cpsa-metabolomics.com

March 11–13, 2019 • Atlanta, GA

Where Technology and Solutions Meet. Where Discovery Meets the Clinic.

Plenary Speaker Athena Zuppa The Children’s Hospital of Philadelphia

Plenary Speaker Neil Spooner Spooner Bioanalytical Solutions

Plenary Speaker Lorin Bachmann VCU Health System

Program Co-Chairs Abhishek Jha Elucidata & Andrew Lee IMCS

Program Co-Chairs Amanda Berg New Objective & Alla Kloss Sanofi

Program Co-Chairs Timothy Olah Bristol-Myers Squibb & Neil Spooner Spooner Bioanalytical Solutions



22nd ANNUAL SYMPOSIUM


www.cpsa-brasil.com

August 19-21, 2019 • São Paulo, Brazil

Where Technology and Solutions Meet. Where Together We Progress.

www.cpsa-analytics.com

Where Technology and Personalized Healthcare Meet!

Where Technology and Solutions Meet!

Clinical and Pharmaceutical Analysts United: Human Wellbeing is Our ResponsibilityOctober 28 -31, 2019 • Philadelphia, PA USA

www.cpsa-usa.com


Clinical & Pharmaceutical Solutions through AnalysisMay 6–9, 2019 • Boston, MA

Feel good about your Pharma QC management?

Feel Better with MerckIf you seek absolute assurance about the rightness of your method development work, if you need to ensure regulatory compliance in quality control, if you require expertise as well as state-of-the-art tools and services during the drug discovery process, just visit www.sial.com/feel-better and feel better.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

MERC180007_ANZ_Feel_Better_Overall_Merck_210x297.indd 1 12.01.18 15:26

Leaders in Flow Technology™

New Objective, Inc. Two Constitution Way Woburn, MA 01801-1023USA

1 781 933 9560 Tel1 781 933 9564 [email protected]

PROUD SPONSOR of CPSA© 2019 New Objective, Inc. All rights reserved. Trademarks are the property of their respective companies.

Leaders in F low Technology™

From the first precision-crafted SilicaTip™ more than twenty years ago to the innovative PicoFrit® column and now the revolutionary PicoChip®, our extraordinary attention to detail and uncompromised performance have provided our community with the quality, performance and robustness they have come to rely upon. New Objective continues to lead innovation in flow technology.

1999Based on SilicaTip reliabilty, the industry-proven PicoFrit column was introduced in response to our customers’ demand for even better performance, reliability, and consistency.

2010Responding again to customer need, the innovative PicoChip was developed. Building on on two decades of of market-driven innovation, PicoChip is the most reliable, robust, and high-performing sample delivery system available for nano- and micro-flow analysis.

1997The first of the PicoTip® line, the SilicaTip™, was manufactured more than twenty years ago in Cambridge, MA. Crafted with consistent precision, the SilicaTip™ has become the backbone of New Objective innovation and performance.

cpsa europe 2019 meeting programme · robert buco waters mateus campos sciex kyle d’silva thermo...

Documents